Quetiapine is not a traditional mood stabilizer like lithium or valproate, but it functions like one in practice. It is FDA-approved to treat both manic and depressive episodes in bipolar disorder, and to prevent them from coming back. By the most widely used clinical definition, a mood stabilizer is a medication with both antimanic and antidepressant actions, and quetiapine checks both boxes. Major psychiatric guidelines now rank it as a first-line treatment across nearly every phase of bipolar disorder.
How Quetiapine Is Officially Classified
Quetiapine belongs to a drug class called atypical antipsychotics. Its formal FDA-approved uses in bipolar disorder cover three distinct phases: acute manic episodes (alone or combined with lithium or valproate), acute depressive episodes as a standalone treatment, and long-term maintenance to prevent relapse when paired with lithium or valproate. It was actually the first antipsychotic approved by the FDA as a standalone treatment for bipolar depression, which set it apart from other drugs in its class.
The term “mood stabilizer” has never had a single locked-down definition in psychiatry. The American Psychiatric Association defined it in 1994 as any medication with both antimanic and antidepressant effects. A broader definition, proposed by Harvard psychiatrist Gary Sachs, says a mood stabilizer simply needs to reduce vulnerability to future episodes of mania or depression without making the current episode worse. Quetiapine meets both criteria, which is why clinicians often refer to it as a mood stabilizer in practice even though its pharmacology places it in the antipsychotic category.
Where It Ranks in Treatment Guidelines
Quetiapine holds a first-line recommendation in virtually every phase of bipolar disorder across multiple international guidelines. The 2023 CANMAT/ISBD guidelines (a widely referenced standard in psychiatry) recommend it as a first-line option for acute mania, acute bipolar I depression, maintenance therapy for bipolar I, and maintenance therapy for bipolar II. For bipolar II depression specifically, quetiapine is the only drug that earned a first-line recommendation.
The U.S. VA/DoD guidelines from the same year give quetiapine a strong recommendation for acute bipolar depression and for preventing the recurrence of manic episodes. The UK’s NICE guidelines also include it among the top-tier choices for mania and hypomania. Few other medications appear this consistently across all phases of the illness, which is part of why quetiapine has become one of the most prescribed drugs for bipolar disorder worldwide.
How It Works in the Brain
Traditional mood stabilizers like lithium work through mechanisms that are still not fully understood but involve signaling pathways inside nerve cells. Quetiapine works differently. It blocks serotonin and dopamine receptors, which is the hallmark of atypical antipsychotics, but it also does several other things that help explain its unusually broad effects on mood.
One key mechanism involves increasing the sensitivity of certain serotonin receptors in the hippocampus (a brain region involved in emotion and memory) to serotonin. This likely contributes to its antidepressant effect. Quetiapine also enhances the activity of norepinephrine-producing neurons through a mechanism involving adrenaline-related receptors, which may further explain why it helps with depression in ways that most antipsychotics do not. On top of that, it blocks histamine receptors (which causes sedation) and several types of adrenaline receptors, giving it a wide pharmacological footprint.
Effectiveness for Mania
In acute mania, quetiapine performs solidly. A large meta-analysis published in The Lancet found it was significantly more effective than placebo, with a standardized effect size of 0.40. It also showed unusually consistent results across different trials, meaning patients responded to it in a relatively predictable way compared to some other antimanic drugs. It can be used alone or added to lithium or valproate for more severe episodes.
Effectiveness for Bipolar Depression
The evidence for bipolar depression is particularly strong. Two large, eight-week trials (known as BOLDER I and II) tested quetiapine at fixed doses of 300 and 600 mg per day in over 1,000 patients with acute bipolar depression. Both doses significantly improved depressive symptoms, anxiety, sleep quality, and overall quality of life compared to placebo. The improvements in sleep were especially notable, with effect sizes of 0.59 at the 300 mg dose and 0.79 at 600 mg. For quality of life, effect sizes were 0.34 and 0.46, respectively.
This matters because bipolar depression is often the harder phase to treat. Many medications that work for mania do little for depression, and standard antidepressants carry the risk of triggering a manic episode. Quetiapine’s ability to treat depression without flipping patients into mania is a major reason it earned such a central role in treatment guidelines.
Preventing Future Episodes
Perhaps the most important quality of a mood stabilizer is its ability to keep mood episodes from coming back. Two randomized trials tested quetiapine combined with lithium or valproate for long-term maintenance. The results were striking: in one study, only 18.5% of patients on quetiapine had a recurrent mood episode compared to 49% on placebo. A second study found nearly identical results, with recurrence rates of 20.3% versus 52.1%. In both cases, quetiapine cut the relapse rate by more than half.
How It Compares to Lithium
Lithium remains the oldest and most studied mood stabilizer, so comparisons between the two are common. For treatment-resistant depression, a 2025 trial found that quetiapine was more effective than lithium at reducing depressive symptoms in real-world clinical practice. An earlier small trial had shown greater improvement with quetiapine starting from day 14, while a larger study found quetiapine was at least as effective as lithium over six weeks. Patients also tended to stay on quetiapine somewhat longer before discontinuing, though the difference was not statistically significant.
The two drugs have very different side effect profiles and monitoring requirements, which often influences the choice between them as much as efficacy data does.
Doses for Different Phases
The dose of quetiapine varies substantially depending on what it’s being used for. For bipolar depression, the typical target is 300 mg per day, taken in the evening. For mania, doses start higher (around 300 mg on day one of the extended-release form) and can go up to 800 mg per day. These are significantly higher than the doses sometimes prescribed off-label for sleep or anxiety, which tend to be 25 to 100 mg.
Metabolic Side Effects
Quetiapine carries meaningful metabolic risks that distinguish it from traditional mood stabilizers like lithium or lamotrigine. Average weight gain ranges from three to nearly six pounds with the immediate-release formulation, placing it in the middle tier among antipsychotics. It is not as problematic as olanzapine (which causes the most weight gain in its class) but is notably worse than drugs like lurasidone or aripiprazole, which are considered more metabolically neutral.
What makes quetiapine unusual is that even at very low doses, it has been associated with significant metabolic changes, including shifts in blood sugar and lipid levels. This means that even patients taking small doses for off-label uses are not necessarily avoiding metabolic risk. Regular monitoring of weight, blood sugar, and cholesterol is standard practice for anyone taking it long-term. Sedation is also very common, particularly early in treatment, due to the drug’s strong blocking of histamine receptors.